Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Topics in HIV Medicine : a Publication of the International AIDS Society, USA|June 9, 2004
Resistance and replication capacity assays: clinical utility and interpretationRichard H Haubrich
Current Opinion in HIV and AIDS|January 6, 2010
Defining treatment failure in resource-rich settingsJeannette L Aldous, Richard H Haubrich
HIV Clinical Trials|October 23, 2013
Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142Jeannie S Huang, Michael D Hughes, Sharon A Riddler, et al.
AIDS Care|June 14, 2021
Pilot comparison of the ease of swallowing of single tablet antiretroviral regimensTommy Parraga Acosta, Zachary Osborn, Jean C Lee, et al.
Cost Effectiveness and Resource Allocation : C/E|May 10, 2011
Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataKit N Simpson, Birgitta Dietz, Robert W Baran, et al.
HIV Clinical Trials|May 18, 2007
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359Richard H Haubrich, Hongyu Jiang, Ronald Swanstrom, et al.
Plos One|June 11, 2015
Genital Cytomegalovirus Replication Predicts Syphilis Acquisition among HIV-1 Infected Men Who Have Sex with MenSara Gianella, Davey M Smith, Eric S Daar, et al.
Open Forum Infectious Diseases|August 28, 2020
PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSMCheríe S Blair, Matthew R Beymer, Ryan M Kofron, et al.
AIDS (London, England)|September 5, 2009
The use of pooled viral load testing to identify antiretroviral treatment failureDavey M Smith, Susanne J May, Josué Pérez-Santiago, et al.
Antiviral Therapy|February 6, 2004
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistanceJoel E Gallant, Peter Z Gerondelis, Mark A Wainberg, et al.
Pageof 4